Skip to main content

Table 1 Demographic and disease-specific characteristics of patients with psoriatic arthritis (PsA), patients with psoriasis (PSO) and healthy controls (HC)

From: Simultaneous quantification of bone erosions and enthesiophytes in the joints of patients with psoriasis or psoriatic arthritis - effects of age and disease duration

  PsA PSO HC P values
Demographic characteristics
 Number of subjects 101 55 47
 Sex (male/female) 50/51 35/20 24/23 0.220
 Age (years) 50.8 ± 13.2 49.0 ± 11.4 45.7 ± 12.9 0.056
 Body mass index 28.1 ± 5.7 27.9 ± 5.6 25.0 ± 4.7 0.011
 Smokers, N (%) 28 (27.7) 16 (29.1) 11 (23.4) 0.875
Disease specific characteristics
 Duration of PSO (years) 18.9 ± 14.8 15.2 ± 15.4 0.071
 Duration of PsA (years) 6.4 ± 7.3
 PASI (units) 3.4 ± 5.5 6.2 ± 8.0 0.007
 HAQ 0.8 ± 0.8 0.4 ± 0.5 0.003
 DAS28-ESR (units) 2.98 ± 1.48
Phenotypic characteristics
 Nail involvement, N (%) 21 (20.8) 28 (50.9) 0.004
 Scalp involvement, N (%) 20 (19.8) 16 (29.1) 0.659
Other clinical characteristics
 Positive ACPA, N (%) 1 (1.0) 0 0.452
 Positive low-titre RF, N (%)a 9 (8.9) 4 (7.3) 0.681
 C-reactive protein (mg/L)b 4.9 ± 6.5 3.8 ± 4.6 0.228
Treatment modalities
 Current csDMARDs, N (%) 52 (51.5) 9 (16.4) < 0.001
 Current bDMARDs, N (%) 49 (48.5) 4 (7.3) < 0.001
 Current Glucocorticoids, N (%) 19 (18.8) 0 (0) 0.001
 Current NSAIDs, N (%) 31 (30.7) 6 (10.9) 0.005
 No systemic treatment, N (%) 13 (12.9) 41 (74.5) < 0.001
  1. ACPA anti-citrullinated protein antibody, bDMARDs biologic disease-modifying anti-rheumatic drugs, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, DAS28-ESR disease activity score 28 based on erythrocyte sedimentation rate, N number, NSAIDs non-steroidal anti-inflammatory drugs, PASI Psoriasis area and severity index, HAQ health assessment questionnaire, RF rheumatoid factor
  2. a< 50 IE/mL
  3. bNormal value < 5 mg/mL